envudeucitinib   Click here for help

GtoPdb Ligand ID: 13205

Synonyms: ESK-001 | ESK001
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The chemical structure for envudeucitinib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a Janus kinase inhibitor with anti-inflammatory potential. It was later disclosed as an orally bioavailable allosteric TYK2 inhibitor, with company code ESK-001 [1,3]. Envudeucitinib targets the allosteric pseudokinase structural domain (JH2) of TYK2.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 107.75
Molecular weight 420.47
XLogP 1.02
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C([2H])([2H])([2H])CC(=O)C1=C(C=C(N=C1)NC(=O)C2CC2)NC3=C(C(=CC=C3)C4=NN(C([2H])([2H])[2H])C=N4)OC
Isomeric SMILES [2H]C([2H])([2H])CC(=O)C1=CN=C(NC(=O)C2CC2)C=C1NC3=CC=CC(C4=NN(C=N4)C([2H])([2H])[2H])=C3OC
InChI InChI=1S/C22H24N6O3/c1-4-18(29)15-11-23-19(26-22(30)13-8-9-13)10-17(15)25-16-7-5-6-14(20(16)31-3)21-24-12-28(2)27-21/h5-7,10-13H,4,8-9H2,1-3H3,(H2,23,25,26,30)/i1D3,2D3
InChI Key FKCATCQHVCOBCX-WFGJKAKNSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Envudeucitinib (ESK-001) was progressed as a clinical candidate for potential to treat inflammatory conditions including plaque psoriasis, SLE and uveitis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06586112 A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis Phase 3 Interventional Alumis Inc
NCT06588738 A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 Phase 3 Interventional Alumis Inc
NCT06846541 Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis Phase 3 Interventional Alumis Inc
NCT05600036 A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis Phase 2 Interventional Alumis Inc 2